Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

NCT04969497 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Treatment A: M207 3.8 mg "MiniMac"
DRUG: Treatment B: M207 3.8 mg "MACAP"
DRUG: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0

Sponsor

Zosano Pharma Corporation